This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
The Freely Filtered team (minus Samira) spent an hour doing a deep dive on the Risk Score for IgA nephropathy and how many grams of IgA a human makes everyday.
Listen
Subscribe
Leave a review on iTunes.
NSMC Intern Daniyal Jafree stepped up to write an excellent tweetorial on the latest NephJC discussion. Take a look.
Welcome to the @NSMCInternship #tweetorial for this week’s study on a new risk prediction tool for IgA nephropathy, appearing in @JAMAInternalMed. Check out these unhappy glomeruli with mesangial IgA deposits in green from https://t.co/5t2NImFGj4 (1/16) pic.twitter.com/nDEkuxduK6
— Nephrology Jrnl Club (@NephJC) June 3, 2019
